Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye scan could spot early signs of wet AMD returning

NCT ID NCT03803631

Knowledge-focused Sponsor: Centre Hospitalier Intercommunal Creteil Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a new, non-invasive eye scan called OCT angiography to see if it can better detect changes in abnormal blood vessels in people with wet age-related macular degeneration (AMD) who are being treated with Eylea. Researchers followed 49 patients to compare the new scan with standard imaging. The goal was to find early signs that the disease might be coming back, which could help doctors adjust treatment sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors detect early signs of wet AMD recurrence using a non-invasive imaging test, potentially improving treatment timing.
What could go wrong
This is a small, completed observational study (49 participants) that does not test a new treatment. The findings may not change current practice without larger validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

49 people

The number who actually took part.

Started

Apr 2018

Finished

Nov 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with wet-AMD (NVC type 1 or 2) diagnosed maximum one week before inclusion and for whom Aflibercept in intra-vitreal injection technic has been prescribed.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Naïve patients * Type 1 or type 2 Choroidal NeoVascularization (CNV) * Age ≥ 55 years * Presence of subfoveal CNV secondary to Age-related Macular Degeneration (AMD) * At the time of inclusion, multimodal imaging should reveal exudative features * Exudative AMD diagnosis established between 1 and 7 days before inclusion * Monitored monthly * Loading phase then bimonthly retreatment. * Signed Informed Consent. * Patient covered by the French Health Insurance Exclusion Criteria: * Polypoidal choroidal vasculopathy * Type 3 neovascularization * Choroidal neovascularization attributable to causes other than AMD * Macular hematoma * Pigment epithelial detachment higher than 150µm * Fibrosis \> 50% lesion on fundus color photography, fibroglial scar * Media opacity annoying acquisition * Retinal vascular occlusion * Diabetic retinopathy * Adult-onset foveomacular vitelliform dystrophy and other pattern dystrophies, * Refractive error \>-6D * Active intraocular inflammation in the study eye * Patient who does not meet the local indication criteria for Eylea® treatment. Contraindications listed in the SmPCs must be taken into account * Patient taking part in an interventional study at the time of enrolment. * Any history of allergy to the antiseptic used during preparation of the eye for the IVT injection in the investigational site (e.g. povidone iodine or chlorhexidine). * Pregnant and lactating women * Stroke and/or myocardial infarction 3 months before inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMD Exudative macular degeneration

Contacts and locations

Locations

  • CHI de Créteil

    Créteil, 94000, France

  • Centre Ophtalmologique d'Imagerie et de Laser,

    Paris, 75015, France

  • Hôpital La Croix Rousse

    Lyon, 69004, France

  • Hôpital Lariboisière, APHP

    Paris, 75010, France

  • Hôpital Pellegrin, CHU de Bordeaux

    Bordeaux, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.